Group items matching

in title, tags, annotations or url

Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front-yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 to researchers with a novel approach to pediatric oncology scientific investigation. That can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of having successfully competed for extramural funding.

Alex's Lemonade Stand Foundation, a nonprofit foundation that has evolved from a young cancer patient's front-yard lemonade stand to a national foundation for childhood cancer, awards grants designed to fill critical voids in current pediatric cancer research. Through its Innovation Grants program, the foundation awards two-year grants of up to $250,000 to researchers with a novel approach to pediatric oncology scientific investigation. That can include a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications, and can demonstrate evidence of having successfully competed for extramural funding.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing research projects on the advanced development of emerging molecular and cellular analysis technologies and technical/analytical validation in an appropriate cancer-relevant biological system. An emerging technology is defined as one that has passed the pilot developmental stage and shows promise, but has not yet been significantly evaluated within the context of its intended use. If successful, these technologies would accelerate research in cancer biology, cancer treatment and diagnosis, early detection and screening, cancer control and epidemiology, and/or cancer health disparities. This FOA solicits projects where proof-of-principle of the proposed technology or methodology has been established and supportive preliminary data are available. Projects proposed to this FOA should reflect the potential to produce a molecular analysis technology with a major impact in a broad area of cancer-relevant research. Projects proposing to use established technologies where the novelty resides in the biological or clinical question being pursued are not appropriate for this solicitation and will not be reviewed.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate Cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of Cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of Cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with Cancer development. This initiative should include demonstration projects that will show how Cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate Cancer research. The purpose of this FOA is to increase case ascertainment and optimize delivery of evidence-based healthcare for individuals at high risk of Cancer due to an inherited genetic susceptibility. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) Recommendation E: "To realize the potential of Cancer prevention and early detection in our nation, NCI should sponsor an initiative to improve the current state of early detection, genetic testing, genetic counseling, and knowledge landscape of the mechanisms and biomarkers associated with Cancer development. This initiative should include demonstration projects that will show how Cancer screening programs can simultaneously save lives, improve quality of life, and reduce healthcare costs."

Founded in 1996, the Marsha Rivkin Center for Ovarian Cancer Research provides funding for multiple efforts, including funding for innovative research pilot studies, scholar grants to up-and-coming investigators to encourage careers in ovarian Cancer research, conducting public early detection screening for ovarian Cancer, and producing nationally and internationally attended research symposia on ovarian Cancer. To that end, the center is accepting applications for pilot study projects in ovarian Cancer research. Through the center's Pilot Study Program, approximately ten one-year $75,000 grants will be awarded to support investigator-initiated projects in all areas of ovarian Cancer research. Projects designed to analyze data from already funded clinical trials also will be considered. Priority will be given to proposals that are innovative, multidisciplinary, likely to lead to submission of grant applications for independently funded investigations, and have translational research potential.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. FOA Emphasis. This FOA utilizes the R33 mechanism and is suitable for projects, which have overcome major feasibility gaps for the technology or methodology as demonstrated with supportive preliminary data but still require further development and rigorous validation to encourage adoption by the research community. Proposed projects should offer the potential to produce a molecular or cellular analysis capability with a major impact in a broad area of cancer-relevant research.

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the inception and early-stage development of highly innovative, molecular and/or cellular analysis technologies with transformative potential. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection, and screening, clinical diagnosis, treatment, control, epidemiology, and/or cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must focus on improving molecular and/or cellular characterizations of cancer. Applications involving an existing technology not yet demonstrated for the proposed cancer-relevant application(s) are also within the scope of this FOA but must involve additional technical modifications and development to allow for the proposed cancer-relevant context of use or some significant question of feasibility exists for achieving the proposed aims. If the research focus for the application involves an existing technology, a clear description of the feasibility risk justifying the use of the R21 mechanism must be included in the application.  Applicants are encouraged to reach out to the Scientific/Research Contact below with any questions.

 The National Cancer Institute's (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to Cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and Cancer researchers who collaborate to advance our understanding of the mechanisms underlying Cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in Cancer research. 

The National Cancer Institutes (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to Cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and Cancer researchers who collaborate to advance our understanding of the mechanisms underlying Cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must demonstrate explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in Cancer research.

The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of Cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in Cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical Cancer research.

The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of Cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in Cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical Cancer research. 

The American Association for Cancer Research is accepting applications for its AACR NextGen Grants for Transformative Cancer Research program. The annual program is designed to stimulate highly innovative research from young investigators. Three-year grants of up to $450,000 will be awarded in support of creative, paradigm-shifting Cancer research that might not be funded through conventional channels. The funds are intended to support expenses related to the research project, which may include salary and benefits of the grant recipient, postdoctoral or clinical research fellows, graduate students (including tuition costs), and research assistants; research/laboratory supplies and equipment; travel applicable to the research project; publication charges for manuscripts that pertain directly to the funded project; and other research expenses and indirect costs. Research projects must represent a highly innovative approach to a major contemporary challenge in Cancer research. The research, which can be in any area of basic, translational or clinical science, must have the potential to lead to groundbreaking discoveries in the field and transform our understanding of the tumorigenesis process and/or ability to treat, detect, or prevent Cancer. To be eligible, applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. In addition, at the start of the grant term on July 1, 2018, applicants must hold a tenure-eligible appointment at the level of assistant professor; have held this appointment for no more than three years; and work at an academic, medical, or research institution anywhere in the world. AACR membership is required.

Founded in 1996, the Marsha Rivkin Center for Ovarian Cancer Research supports public early detection screening for ovarian Cancer, produces nationally and internationally attended research symposia, and provides funding for innovative ovarian Cancer research and scholar grants to up-and-coming investigators. The center is accepting applications for pilot study projects in ovarian Cancer research. Through the center's Pilot Study Program, approximately ten one-year grants of $75,000 will be awarded to support investigator-initiated projects in all areas of ovarian Cancer research. Projects designed to analyze data from already funded clinical trials also will be considered. Priority will be given to proposals that are innovative, multi-disciplinary, and likely to lead to the submission of grant applications for independently funded investigations. Investigators at all levels are encouraged to apply.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate Cancer research. Specifically, this FOA targets the following area designated as scientific priority by the Blue Ribbon Panel (BRP): Recommendation B. Create a translational science network devoted exclusively to immunotherapy approaches to treat and prevent adult Cancers. The goal of the network is to foster collaborative team science approaches to accelerate the discover of new immune targets and evaluate novel immune-based therapies and combination approaches that eliminate established Cancers in adults or to prevent Cancers before they occur. The purpose of this FOA is to establish a Data Management and Resource-sharing Center to provide overall support for the Immuno-Oncology Translational Network (IOTN) and to integrate the research activities of the IOTN with other Cancer Moonshot Initiative programs.

This Administrative Supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate Cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative. Based on the recommendation to intensify research and form highly dynamic and collaborative networks of investigators to advance our understanding of fusion oncoproteins as drivers of childhood Cancers, this FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations to perform research within the scientific scope of the parent grant that will lead to better understanding of the mechanisms of action of fusion oncoproteins as drivers of childhood sarcomas, brain Cancers, and high risk leukemias.

The Breakthrough Fellowship Award mechanism is being offered for the first time in FY16. The Breakthrough Fellowship Award supports recent doctoral or medical graduates in pursuit of innovative, high-impact breast cancer research during their postdoctoral fellowship and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research. Those individuals should be exceptionally talented researchers who have demonstrated that they are the "best and brightest" of their peers. Applicants for this award must exhibit a strong desire to pursue a career in breast cancer research, with clear evidence for a researcher development plan that will lead to a successful independent career in breast cancer. Applicants must also demonstrate that the proposed research has high potential to lead to or make breakthroughs in breast cancer.

This Funding Opportunity Announcement (FOA) encourages research projects focused on adducts to cellular macromolecules as indicators of exposures to cancer risk factors relevant to human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. These projects should explore the basic aspects of adducts/adductomics that may have a potential utility in cancer detection, cancer prevention, and/or assessing cancer risks. The projects should be relevant to adducts in humans and human populations but may be conducted using various model systems (e.g., cultured cells, animals, etc.). The use of human biospecimens is encouraged and expected if appropriate but not required. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National cancer Institute (NCI) Provocative Questions initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative includes an updated set of 12 PQs. Each research project proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific PQ selected from the list. Projects proposed to address specific PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen. Also listed under R21

Breakthrough Fellowship Award supports recent doctoral or medical graduates in pursuit of innovative, high-impact breast cancer research during their postdoctoral fellowship and allows them to obtain the necessary experience for an independent career at the forefront of breast cancer research. Those individuals should be exceptionally talented researchers who have demonstrated that they are the "best and brightest" of their peers. Applicants for this award must exhibit a strong desire to pursue a career in breast cancer research, with clear evidence for a researcher development plan that will lead to a successful independent career in breast cancer. Applicants must also demonstrate that the proposed research has high potential to lead to or make breakthroughs in breast cancer.

This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver Cancer. The Consortium will consist of several Translational Research Centers (TRCs, to be supported by this U01 FOA) and a Data Management and Coordinating Center (DMCC, to be supported a companion U24 FOA, RFA-CA-17-028). The TRCs will conduct studies to improve the surveillance of liver Cancer in members of high-risk populations, increase the fraction of liver Cancer detected at an early stage, and better stratify patients at risk of developing liver Cancer. Research to be conducted by TRCs must be based on appropriate range of biospecimens from cohorts that are focused on cirrhotic patients. A major collaborative effort of the TRCs will be the establishment of a well annotated repository of biospecimens. Biospecimens (blood, other body fluids, and, when feasible, liver tissue) may be already available and/or may be prospectively collected.

This Funding Opportunity Announcement (FOA) encourages collaborative applications that will contribute to the identification and characterization of patients at risk of developing cancer treatment-related cardiotoxicity. The primary intent is to mitigate cardiovascular dysfunction while optimizing cancer outcomes. To accomplish this, methods that evaluate cardiac risk prior to treatment and integrate evidence-based cancer treatment regimens with screening, diagnostic, and/or management strategies are sought. Research applications should focus on mitigation/management of adverse effects associated with anti-cancer treatments including: cytotoxic chemotherapies, targeted agents, immunomodulatory therapies and radiation (that occur during cancer treatment and/or long-term survivorship) as defined by cardiac specific common terminology criteria for adverse events (CTCAE).